| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 940.2 | 840.8 | 720.4 |
| Other income | 18.1 | 25.4 | 21.6 |
| Total income | 958.3 | 866.2 | 742.0 |
| Profit before exceptional items & tax | 193.5 | 206.6 | 133.3 |
| Profit before tax | 193.5 | 206.6 | 133.3 |
| Net profit | 143.5 | 159.4 | 99.1 |
| Operating margin | 20.2% | 23.9% | 18.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +44.80% |
|---|---|
| Net profit, quarter on quarter | -10.00% |
| Revenue, year on year | +30.50% |
| Operating profit, year on year | +57.00% |
| Operating profit, quarter on quarter | -3.20% |
BSE results filing, NSE: MARKSANS. Figures extracted from the filing.
Marksans Pharma Ltd: key numbers
- Share price
- ₹326.75
- Market cap
- ₹14,807 Cr
- Revenue (annual)
- ₹2,951 Cr
- Net profit (annual)
- ₹417.9 Cr
- P/E (TTM)
- 28.6×Sector 41.3×
- Promoter holding
- 43.87%+0.00% QoQ
- FII holding
- 19.06%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Marksans Pharma Ltd
All →Marksans Pharma Results Update
Marksans Pharma reported Q2FY27 revenue of ₹940 crore and H1FY27 PAT of ₹303 crore. EBITDA grew 48% to a record ₹214 crore in the quarter.
Marksans Pharma Investor Presentation: Key Takeaways
Q2FY27 revenue ₹940cr (+30.5% YoY), EBITDA ₹214cr at 22.8% margin (+274bps), PAT ₹143.5cr (+44.8%). H1 PAT ₹303cr; net cash ₹1,095cr; Europe front-end being built.
Marksans Pharma Board Meeting Date
Marksans Pharma scheduled its Board meeting for November 4, 2026, to approve Q1/H1 unaudited results. No material decision has been taken yet.
Marksans Pharma Other Announcement
Periodic quarterly shareholding pattern filing for Marksans Pharma Ltd. This document provides the latest breakdown of shareholder categories as mandated by SEBI.
Marksans Pharma Promoter Selling (Off-Market)
Director Sandra Saldanha gifted 2,28,273 shares of Marksans Pharma Ltd to her daughters in an off-market transaction. This internal transfer reallocates promoter-group equity holdings.
Marksans Pharma Other Announcement
Marksans Pharma intimated shareholders about SEBI's extended special window (Feb 2026–Feb 2027) for re-lodgement of pre-April-2019 physical share transfer deeds. No new business, capital, or operational event is disclosed.